Table 2.
The ranges of the metabolites concentrations in PDE patients and control groups.
| Samples | α-AASA | P6C | α-AASA-P6C | PA | α-AAA | |
|---|---|---|---|---|---|---|
| PDE patients/(1.3–8.6y), n = 15 | Plasma (µmol/L) | 4.89 (0.59–14.57) | 5.99 (2.95–11.58) | 10.87 (4.40–24.17) | 4.45 (1.49–8.12) | 4.05 (2.19–6.69) |
| Serum (µmol/L) | 3.86 (0.28–11.36) | 5.93 (3.25–10.17) | 9.79 (3.73–20.65) | 4.72 (1.63–8.29) | 4.49 (2.55–6.95) | |
| DBS (µmol/L) | 3.80 (1.17–9.49) | 0.64 (0.38–1.56) | 4.44 (2.30–10.04) | 3.38 (1.38–5.81) | 5.64 (2.66–9.45) | |
| Urine (µmol/mmolCr) | 31.4 (1.81–94.35) | 10.53 (1.41–27.66) | 41.95 (3.22–122.00) | 0.13 (0.02–0.38) | 27.99 (12.25–74.89) | |
| DUS (µmol/mmolCr) | 30.05 (2.07–86.32) | 10.44 (2.69–28.55) | 40.49 (4.76–114.87) | 0.13 (0.01–0.37) | 28.54 (10.64–75.47) | |
| Controls/(1–13y) | Samples/mean ages (ranges) | α-AASA | P6C | α-AASA-P6C | PA | α-AAA |
| Plasma (µmol/L)/n = 28 | 0.00 | 0.40 (0.25–0.58) | 0.40 (0.25–0.58) | 1.50 (0.38–7.61) | 2.22 (1.04–4.72) | |
| Serum (µmol/L)/n = 25 | 0.00 | 0.35 (0.34–0.378) | 0.35 (0.34–0.38) | 0.91 (0.33–3.52) | 2.00 (0.97–4.23) | |
| DBS (µmol/L)/n = 25 | 0.02 (0.00–0.08) | 0.17 (0.15–0.23) | 0.19 (0.15–0.26) | 0.81 (0.17–3.37) | 1.60 (0.91–2.90) | |
| Urine (µmol/mmolCr)/n = 25 | 0.12 (0.00–0.53) | 0.43 (0.10–1.10) | 0.55 (0.18–1.11) | 0.17 (0.00–0.94) | 15.92 (2.62–51.12) | |
| DUS (µmol/mmolCr)/n = 25 | 0.10 (0.00–0.67) | 0.41 (0.10–1.13) | 0.51 (0.18–1.13) | 0.31 (0.01–1.19) | 19.72 (2.51–53.70) |